Search

Jabbed demonstrates that the medical procedure hailed as the greatest medical advancement in history—vaccines—is a racket run by criminals and gullible believers who have replaced vaccine science with the religion of vaccinology. Vaccine marketers teach believers to fear, shame, and scapegoat anyone foolish enough to question the sanctity of vaccines. Such an environment is not the domain of science; rather it's the breeding ground of tyranny.Jabbed exposes this tyranny. From polio and smallpox to medical journals, medical curricula, congressional hearings, regulatory policies, White House statements, and executive orders, Jabbed shines light on the dark underbelly of Big Pharma, Big Medicine, and Big Government.A vaccine informed public is the only thing that will have the power to stop vaccine industry sociopaths and to hold them accountable for their crimes.Jabbed informs and immunizes against three of the most dangerous epidemics in history: tyranny, greed, and corruption. Once immunized, the growing vaccine-informed community will have the power to stand up and dismantle the vaccine paradigm and program and to punish the perpetrators of what may well be the greatest medical fraud ever perpetrated on the human race: vaccines.

A comprehensive and granular insight into the challenges of promoting rational medicine, this book serves as an essential resource for health policy makers and researchers interested in national medicines policies. Country-specific chapters have a common format, beginning with an overview of the health system and regulatory and policy environments, before discussing the difficulties in maintaining a medicines supply system, challenges in ensuring access to affordable medicines and issues impacting on rational medicine use. Numerous case studies are also used to highlight key issues and each chapter concludes with country-specific solutions to the issues raised. Written by highly regarded academics, the book includes countries in Africa, Asia, Europe, the Middle East and South America.

Across the world, developing countries are attempting to balance the international standards of intellectual property concerning pharmaceutical patents against the urgent need for accessible and affordable medicines. In this timely and necessary book, Monirul Azam examines the attempts of several developing countries to walk this fine line. He evaluates the experiences of Brazil, China, India, and South Africa for lessons to guide Bangladesh and developing nations everywhere. Azam's legal expertise, concern for public welfare, and compelling grasp of principal case studies make Intellectual Property and Public Health in the Developing World a definitive work. The developing world is striving to meet the requirements of the World Trade Organization's TRIPS Agreement on intellectual property. This book sets out with lucidity and insight the background of the TRIPS Agreement and its implications for pharmaceutical patents, the consequences for developing countries, and the efforts of certain representative nations to comply with international stipulations while still maintaining local industry and public health. Azam then brings the weight of this research to bear on the particular case of Bangladesh, offering a number of specific policy recommendations for the Bangladeshi government—and for governments the world over. Intellectual Property and Public Health in the Developing World is a must-read for public policy-makers, academics and students, non-governmental organizations, and readers everywhere who are interested in making sure that developing nations meet the health care needs of their people.

'One third of the world's population lack effective access to quality assured essential medicines used rationally'. When WHO first made this statement fifteen years ago, there was general concern that medical miracles such as antibiotics, antiparasitic medicines, vaccines and anal­ gesics would not be available to many people. Today, the proportion of those lack­ ing access is lower in Asia and Latin America and higher in Africa but there are probably about two billion people in this situation. This book describes the many problems involved, and then puts together possible solutions based on country expe­ riences in a comprehensive and coherent manner. Many people lack access to essential medicines because they and their countries are poor, and because of inefficiencies in their health systems. We know that in low and middle income countries between 25 and 40 per cent of health expenditure is on medicines, and that most of that expenditure is out of pocket. Often this amounts to less than US $ 2 per head per year! In contrast, high income countries spend only 8 to 15 per cent of health expenditure on medicines, and this is mostly paid for by health insurance or social security funds. High income country expen­ diture may be over US $ 400 per person per year! So managing the scanty resources available in low income countries becomes all the more important.

For more than 50 years, low-cost antimalarial drugs silently saved millions of lives and cured billions of debilitating infections. Today, however, these drugs no longer work against the deadliest form of malaria that exists throughout the world. Malaria deaths in sub-Saharan Africa—currently just over one million per year—are rising because of increased resistance to the old, inexpensive drugs. Although effective new drugs called'artemisinins'are available, they are unaffordable for the majority of the affected population, even at a cost of one dollar per course. Saving Lives, Buying Time: Economics of Malaria Drugs in an Age of Resistance examines the history of malaria treatments, provides an overview of the current drug crisis, and offers recommendations on maximizing access to and effectiveness of antimalarial drugs. The book finds that most people in endemic countries will not have access to currently effective combination treatments, which should include an artemisinin, without financing from the global community. Without funding for effective treatment, malaria mortality could double over the next 10 to 20 years and transmission will intensify.